Certolizumab pegol vs placebo
Any severe adverse event during maintenance treatment · people with Crohn's disease who responded to CZP remission‐induction treatment
Certolizumab pegol showed no clear difference in serious adverse events during remission maintenance treatment(1 RCT,… compared with placebo (low certainty).
1 finding from 1 review
- Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease 2022 · Cochrane Headline outcomes onlyRR 0.84 [0.4, 1.78]Studies not reportedLow